Daily Sepsis Research Analysis
Analyzed 26 papers and selected 3 impactful papers.
Summary
Three high-impact studies advance sepsis science across therapy, prevention, and organ-specific vulnerability. A domain-specific HMGB1-neutralizing DNA aptamer improved survival in polymicrobial sepsis, a high-throughput vaccinology platform yielded pneumococcal antigens protecting against pneumonia and sepsis in mice, and aging-related autophagy defects mediated by TFEB were shown to drive susceptibility to septic acute kidney injury, with pharmacologic TFEB activation mitigating injury.
Research Themes
- Immunomodulatory therapeutics targeting DAMPs in sepsis
- High-throughput vaccine antigen discovery to prevent invasive infections and sepsis
- Aging biology and autophagy dysregulation driving organ-specific sepsis susceptibility
Selected Articles
1. Aptamer targeting HMGB1 attenuates inflammatory disease via domain-specific antagonism.
ZH-1a, a DNA aptamer with nanomolar affinity to the HMGB1 B-box, neutralized extracellular HMGB1, dampened inflammatory signaling, and improved survival in polymicrobial sepsis. The aptamer also reduced late-phase systemic inflammation and organ injury across multiple in vivo models, supporting HMGB1 neutralization as a therapeutic strategy.
Impact: Provides domain-specific biologic antagonism against a late mediator of sepsis with survival benefit, representing a potentially paradigm-shifting immunomodulatory approach. The study integrates target validation with therapeutic proof-of-concept across models.
Clinical Implications: If translated, HMGB1-neutralizing aptamers could complement antibiotics and source control by suppressing damaging late-phase inflammation, potentially benefiting patients with persistent systemic inflammation or organ failure after initial resuscitation.
Key Findings
- Identified ZH-1a, a DNA aptamer (Kd = 2.1 nM) that preferentially binds the HMGB1 B-box.
- ZH-1a suppressed HMGB1-induced cytokine release and NF-κB activation in macrophages.
- In vivo, ZH-1a reduced late-phase systemic inflammation, improved survival in polymicrobial sepsis, and mitigated multiorgan injury.
Methodological Strengths
- Domain-specific targeting with high-affinity aptamer validated by SELEX and functional assays.
- Robust in vivo validation across multiple inflammatory and sepsis models with survival endpoints.
Limitations
- Preclinical models; human pharmacokinetics, immunogenicity, and safety are unknown.
- HMGB1 pleiotropy and timing of intervention may affect therapeutic windows and generalizability.
Future Directions: Optimize aptamer stability and delivery, perform large-animal sepsis studies, define pharmacodynamics/biomarkers for patient selection, and initiate phase I trials possibly in combination with standard sepsis care.
Damage-associated molecular patterns (DAMPs) are key mediators of inflammatory disease, among which HMGB1 is a prototypical extracellular alarmin and an attractive therapeutic target. Here, we report ZH-1a, a high-affinity DNA aptamer (Kd = 2.1 nM) identified through SELEX and sequence optimization, that preferentially recognizes the proinflammatory B-box region of HMGB1. ZH-1a functions as an extracellular HMGB1-neutralizing aptamer and suppresses HMGB1-induced inflammatory signaling, including cytokine secretion and NF-κB activation in macrophages. In vivo, ZH-1a reduced late-phase systemic inflammation and multiorgan injury in LPS-induced endotoxemia, improved survival in polymicrobial sepsis, and attenuated inflammatory responses and organ damage in an HMGB1-challenge model. In addition, ZH-1a alleviated joint inflammation and structural damage in collagen-induced arthritis, and further enhanced the therapeutic efficacy of methotrexate. Together, these findings establish ZH-1a as a promising anti-inflammatory aptamer targeting HMGB1 and support aptamer-based neutralization of pathogenic extracellular HMGB1 as a therapeutic strategy for inflammatory disease.
2. High-throughput antigen discovery using Functional Genomic Vaccinology (FGV) identifies protective Streptococcus pneumoniae vaccine candidates.
A scalable Functional Genomic Vaccinology workflow integrated genome-wide prediction, proteome-scale screening, and immunogenicity validation to prioritize pneumococcal antigens. A four-antigen multicomponent vaccine protected mice against pneumonia and sepsis, with epitope mapping highlighting protective regions.
Impact: Introduces an experimentally driven, high-throughput platform that can accelerate vaccine discovery against sepsis-causing bacteria, with in vivo protection as proof-of-concept.
Clinical Implications: FGV-prioritized antigens could inform next-generation pneumococcal vaccines to reduce invasive pneumococcal disease and sepsis burden, especially in high-risk populations and regions with serotype replacement.
Key Findings
- Established a high-throughput Functional Genomic Vaccinology platform integrating prediction, screening, and validation.
- From 222 conserved S. pneumoniae proteins, 40% elicited significant IgG; 22 candidates were prioritized using human sera.
- A four-antigen multicomponent vaccine protected mice from pneumonia and sepsis; epitope mapping identified protective regions.
Methodological Strengths
- Proteome-scale screening coupled with human-sera-guided prioritization increases translational relevance.
- In vivo efficacy testing with defined multicomponent formulation and epitope mapping.
Limitations
- Protection demonstrated only in mouse models; human immunogenicity and safety remain unknown.
- Breadth against diverse clinical isolates and durability of protection were not assessed.
Future Directions: Advance prioritized antigens to GMP-grade production, test in additional preclinical species, evaluate breadth across clinical isolates, and initiate early-phase human immunogenicity trials.
The discovery of protective antigens remains a major bottleneck in bacterial vaccine development. To overcome this limitation, we present Functional Genomic Vaccinology (FGV), a high-throughput antigen discovery platform integrating genome-wide antigen prediction, proteome-scale screening, and experimental immunogenicity validation to identify protective bacterial antigens. Using FGV, 222 conserved S. pneumoniae proteins are expressed in vitro, incorporated into a protein microarray, and coupled to magnetic beads for mouse vaccination. Protein array analysis shows significant IgG responses in 40% of the screened proteins. Antigen-specific responses measured in human sera guide the prioritisation of 22 candidates, which undergo further studied for their serological and Th17 responses. Four antigens combined in a multicomponent vaccine induces protection from pneumonia and sepsis in mice, with epitope mapping revealing potential protective sites for each protein. These results establish FGV as a scalable, experimentally driven approach for bacterial vaccine discovery and demonstrate its applicability in developing protective pneumococcal vaccines.
3. Down-Regulation of TFEB With Defective Autophagy in the Susceptibility of Aging Kidneys to Septic Acute Kidney Injury.
Aging kidneys exhibit impaired autophagy activation during septic AKI, driven in part by TFEB down-regulation. Restoring autophagic flux via TFEB overexpression or a curcumin analog TFEB activator ameliorated injury in senescent tubular cells and reduced LPS-induced AKI in aged mice.
Impact: Defines a mechanistic basis for the heightened susceptibility of elderly patients to SA-AKI and proposes TFEB-driven autophagy enhancement as a therapeutic strategy.
Clinical Implications: Targeting TFEB-autophagy pathways could inform nephroprotective strategies in elderly septic patients at high risk for SA-AKI, warranting translational development of TFEB activators.
Key Findings
- Aging kidneys showed impaired autophagy activation in murine SA-AKI models.
- TAT-Beclin-1 reduced LPS-induced apoptosis and inflammation in senescent proximal tubular cells.
- TFEB overexpression restored autophagy and protection in senescent cells; in vivo TFEB activator C1 enhanced autophagy and reduced LPS-induced AKI in aged mice.
Methodological Strengths
- Integration of single-cell transcriptomics with in vitro and in vivo functional validation.
- Use of both genetic (TFEB overexpression) and pharmacologic (C1) modulation to triangulate causality.
Limitations
- Predominantly LPS-based AKI models; polymicrobial or ischemic models were not detailed.
- Translational relevance to human elderly patients requires validation and pharmacokinetics/safety data for TFEB activators.
Future Directions: Assess TFEB activation strategies in polymicrobial sepsis models, validate in human kidney tissues/organoids from elderly patients, and develop clinically tractable TFEB modulators.
Sepsis-associated acute kidney injury (SA-AKI) is a common and devastating disease that has a significantly higher incidence and greater severity in elderly patients, but the molecular basis underlying SA-AKI in the elderly is largely unknown. Recent studies have proved autophagy as an intrinsic protective mechanism against AKI; however, the role and regulation of autophagy in aging kidneys remain unclear. Here we demonstrate that defective autophagy activation in aging kidneys is a key to their susceptibility to SA-AKI. In our experiments, the ability of autophagy activation was impaired in aging kidneys in response to SA-AKI in mice. In vitro, activation of autophagy with TAT-Beclin-1 peptide mitigated lipopolysaccharide (LPS)-induced apoptosis and inflammation in senescent renal proximal tubular cells. Single-cell sequencing revealed significant age-related alterations in autophagy-associated genes in septic AKI, including TFEB. Overexpression of TFEB could partially restore autophagic activity in senescent renal tubular cells and protect them from LPS-induced damage. Moreover, in vivo treatment with the curcumin analog C1 (a TFEB activator) enhanced autophagic function in aging kidneys and reduced LPS-induced AKI. These results demonstrate the defective autophagy activation in aging kidneys, which contributes to the SA-AKI sensitivity and susceptibility in the elderly, suggesting a therapeutic strategy by enhancing autophagy.